Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01536626

BIASP-1925

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.

Enrollment: 211 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Type 2 diabetic subjects treated with BHI 30

Trial design

211 participants in 1 patient group

BIAsp 30 users

Treatment:

Drug: biphasic insulin aspart 30